Mucocutaneous candidiasis (CMC) refers to a heterogeneous group of diseases characterized by recurrent or persistent superficial infections of the skin, mucous membranes and nails with Candida organisms, usually Candida albicans. Mucocutaneous candidiasis affects men and women equally and usually develops during childhood. MC usually manifests in infancy or early childhood (60-80% of cases) with a mean age of onset of 3 years. Onset or delayed reporting of diseases in adults and may be associated with thymoma, myasthenia gravis, and abnormal bone marrow. Mucocutaneous candidiasis is also known as Candida Related Complex. Mucocutaneous candidiasis is a rare disease caused by fungus.
The fungus can cause infections of the mouth (thrush) and infections of the scalp, skin, nails, and the membranes lining the mouth, eyes, digestive tract and reproductive system. Symptoms may include hoarseness, dysphagia, and hemoptysis. There was little correlation between oral lesions and the involvement of the larynx. In the case of mucocutaneous candidiasis, the body is less able to combat fungal infections, including fungal infections. These disorders may be limited to the skin surface, with little propensity for systemic disease. The disorder can affect a nail or cause disfiguring rash that covers the face and scalp. The hair may fall. Hepatitis and chronic lung disease sometimes develop. Mucocutaneous candidiasis patients have a higher incidence of autoimmune diseases.
The treatment is divided into 3 main categories: antifungal agents, immune therapy and combination therapy. Many good antifungal agents are available and usually effective, however, after discontinuation of therapy for most, patients with recurrence. Ketoconazole orally and injections of thymosin and levamisole may have a positive effect. Acyclovir may be indicated in viral infections. Replacement therapy with iron (given orally or IM) may also be necessary. Most patients with mucocutaneous candidiasis are treated that are specific for fungal infections. Miconazole and nystatin are sometimes useful, but ultimately fail to control this infection. Immunotherapies are under investigation and have been used with some success. Terbinafine has been used effectively against disorders mucocutaneous candidiasis.
Mucocutaneous Candidiasis Treatment Tips
1. Fluconazole also be effective in the treatment of mucocutaneous candidiasis.
2. Miconazole and nystatin are useful, but ultimately fail to control this infection.
3. Microscopy and culture of skin swabs and scrapings to confirm the presence of organisms.
4. Terbinafine has been used effectively against disorders mucocutaneous candidiasis.
5. Immunotherapy is used with some cases.

Tags: Candidiasis, Mucocutaneous, Tips, Treatment

This entry was posted on Saturday, September 26th, 2009 at 2:57 pm and is filed under Candidiasis. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.